Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EFFECT trial of fluconazole plus flucytosine versus fluconazole alone in asymptomatic cryptococcal antigen-positive adults with advanced HIV
ISRCTN30579828Phase 3Completed
- Sponsor
- St George's, University of London
- Start
- May 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
01
Overview
Phase 3, randomised, open-label trial in cryptococcosis and human immunodeficiency virus infection (HIV) comparing Fluconazole plus flucytosine with Fluconazole alone (2 arms). Primary endpoint: All-cause mortality at 6 months. Started May 2022; status: completed.
02
Drugs
fluconazoleflucytosine
03
Conditions
cryptococcosishuman immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on ISRCTN30579828.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN30579828.